Arthur Trust, DO
Pulmonary Disease · New Hyde Park, NYNPI 1457448169
Payments from drug & device makers
Across 9 payments — averaging $46.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$202
- Sanofi-aventis U.S. LLC$100
- Genentech USA, Inc.$40
- Amgen$38
- Mylan Specialty L.p.$18
- Insmed, Inc.$17
What the payments were for
- Food & beverage$5614%
- Education$35986%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 3 | $202 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Genentech USA, Inc. | 1 | $40 |
| Amgen | 2 | $38 |
| Mylan Specialty L.p. | 1 | $18 |
| Insmed, Inc. | 1 | $17 |
How this compares
$415 in reported general payments places this provider in the 35th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 33 | $509,671 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 339 | $283,193 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 164 | $117,356 |
| Breo ElliptaFluticasone/Vilanterol | 213 | $114,373 |
| XareltoRivaroxaban | 52 | $51,950 |
| Spiriva RespimatTiotropium Bromide | 60 | $50,141 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 51 | $33,288 |
| EliquisApixaban | 30 | $33,147 |
| SymbicortBudesonide/Formoterol Fumarate | 75 | $26,468 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 31 | $25,127 |
| Arnuity ElliptaFluticasone Furoate | 77 | $24,408 |
| Incruse ElliptaUmeclidinium Bromide | 37 | $22,218 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 119 | $19,134 |
| JanuviaSitagliptin Phosphate | 12 | $18,789 |
| Advair HfaFluticasone Propion/Salmeterol | 23 | $17,077 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in New Hyde Park
- Arunabh TalwarNew Hyde Park$759K
- Jonathan IlowiteNew Hyde Park$703K
- Harly GreenbergNew Hyde Park$300K
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- R WhiteRochester$3.1M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
- Negin HajizadehGreenport$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.